Navigation Links
Amylin Pharmaceuticals to Webcast First Quarter Results
Date:4/9/2009

SAN DIEGO, April 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2009 on Thursday, April 16, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the first quarter of 2009.

The call will be webcast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 770-7051 (U.S./Canada) or (617) 213-8064 (international), Conference ID# 39859682. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), Conference ID# 59408065.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
2. Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
3. Amylin Pharmaceuticals Reports 2008 Financial Results
4. Amylin Pharmaceuticals to Webcast Year-End Results
5. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
6. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. Lilly and Amylin Set Date and Time for Conference Call
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Amylin Pharmaceuticals Reports First Quarter Financial Results
11. Amylin Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left ... she took with her a dream to make nursing education more relevant and prepare ... communication skills were integrated into healthcare provider education. , “The human element ...
(Date:8/17/2017)... ... August 17, 2017 , ... The line-up includes voices from all ... grow a dental practice in a competitive market environment where Corporate Dentistry is making ... just transform you and your practice.” says Daniel A. ‘Danny’ Bobrow, AIM Dental Marketing’s ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... distinguishes herself once more by being among Houston’s first plastic surgeons to offer ... quality plastic surgery care without disrupting busy schedules and maintaining the utmost discretion ...
(Date:8/17/2017)... ... 17, 2017 , ... Florida Hospital Zephyrhills showcased its newly ... The newly renovated ER was designed with patients in mind and offers: 24 ... to deliver patient results, improve efficiencies and reduce length of stay, two pirate-themed ...
(Date:8/17/2017)... ... , ... With the introduction of new devices, new features, and updates to ... smartwatch market. As of June 2017, nearly nine percent of U.S. consumers aged 18+ ... according to latest WEAR Report Industry Overview and Forecast from NPD’s Connected Intelligence, growth ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) today announced ... Aug. 7, 2017. ... and will serve as president emeritus during a planned, 90-day ... multiple leadership roles since he joined Diplomat with the acquisition ... decisive, strategic leadership which continues to benefit our patients and ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: